OP09
Anti-p53 (Ab-2) (Pantropic) Mouse mAb (PAb1801)
liquid, clone PAb1801, Calbiochem®
Bejelentkezésa Szervezeti és Szerződéses árazás megtekintéséhez
Összes fotó(1)
About This Item
UNSPSC kód:
12352203
NACRES:
NA.43
klón:
PAb1801, monoclonal
application:
faj reaktivitás:
human
citations:
20
Javasolt termékek
biológiai forrás
mouse
Minőségi szint
antitest forma
purified antibody
antitest terméktípus
primary antibodies
klón
PAb1801, monoclonal
Forma
liquid
tartalmaz
≤0.1% sodium azide as preservative
faj reaktivitás
human
nem léphet reakcióba
mouse, rat
gyártó/kereskedő neve
Calbiochem®
tárolási körülmény
do not freeze
izotípus
IgG1
kiszállítva
wet ice
tárolási hőmérséklet
2-8°C
célzott transzláció utáni módosítás
unmodified
Géninformáció
human ... TP53(7157)
Általános leírás
Purified mouse monoclonal antibody generated by immunizing BALB/c mice with the specified immunogen and fusing splenocytes with SP2/0 Ag14 mouse myeloma cells (see application references). Recognizes the ~53 kDa mutant and wild-type forms of p53.
Recognizes the ~53 kDa wild-type and mutant p53 protein in A-431 cells and breast carcinoma tissue.
This Anti-p53 (Ab-2) (Pantropic) Mouse mAb (PAb1801) is validated for use in Frozen Sections, Gel Shift, Immunoblotting, IP, Paraffin Sections for the detection of p53 (Ab-2) (Pantropic).
Immunogén
Epitope: within amino acids 46-55 of human p53
Human
a human p53 fusion protein
Alkalmazás
Frozen Sections (5 µg/ml)
Gel Shift (see comments)
Immunoblotting (2.5 µg/ml)
Immunoprecipitation (1 µg/sample)
Paraffin Sections (5 µg/ml, pepsin, trypsin, or heat pre-treatment required)
Gel Shift (see comments)
Immunoblotting (2.5 µg/ml)
Immunoprecipitation (1 µg/sample)
Paraffin Sections (5 µg/ml, pepsin, trypsin, or heat pre-treatment required)
Kiszerelés
Please refer to vial label for lot-specific concentration.
Figyelmeztetés
Toxicity: Standard Handling (A)
Fizikai forma
In 50 mM sodium phosphate buffer, 0.2% gelatin, pH 7.5.
Analízis megjegyzés
Negative Control
SK-OV-3 cells or normal skin
SK-OV-3 cells or normal skin
Positive Control
A431 cells or breast carcinoma tissue
A431 cells or breast carcinoma tissue
Egyéb megjegyzések
El-Deiry, W.S., et al. 1994. Cancer Res.54, 1169.
Greenblatt, M.S., et al. 1994. Cancer Res.54, 4855.
Barak, Y., et al. 1993. EMBO J.12, 461.
Kastan, M.B., et al. 1992. Cell71, 587.
Kuerbitz, S.J. 1992. Proc. Natl. Acad. Sci. USA89, 7491.
Lane, D.P. 1992. Nature358, 15.
Kastan, M.B., et al. 1991. Cancer Res.51, 6304.
Greenblatt, M.S., et al. 1994. Cancer Res.54, 4855.
Barak, Y., et al. 1993. EMBO J.12, 461.
Kastan, M.B., et al. 1992. Cell71, 587.
Kuerbitz, S.J. 1992. Proc. Natl. Acad. Sci. USA89, 7491.
Lane, D.P. 1992. Nature358, 15.
Kastan, M.B., et al. 1991. Cancer Res.51, 6304.
Wild-type p53 has a short half-life and is present in low amounts in cells. For immunoprecipitation, increasing the amount of sample to be immunoprecipitated and applied to the gel may help visualize wild-type p53; short incubation times with 35S-Met (≤ 1 h) will help reduce background. For immunoblots of wild-type p53, maximize sensitivity by preconcentrating samples by immunoprecipitation with Cat. No. OP09, then immunoblot using Cat. No. PC35 and chemiluminescent detection. For a gel shift assay, use Cat. No. OP09L and resuspend in 100 µl buffer. Antibody should be titrated for optimal results in individual systems.
Jogi információk
CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany
Nem találja a megfelelő terméket?
Próbálja ki a Termékválasztó eszköz. eszközt
Tárolási osztály kódja
10 - Combustible liquids
WGK
nwg
Lobbanási pont (F)
Not applicable
Lobbanási pont (C)
Not applicable
Analitikai tanúsítványok (COA)
Analitikai tanúsítványok (COA) keresése a termék sarzs-/tételszámának megadásával. A sarzs- és tételszámok a termék címkéjén találhatók, a „Lot” vagy „Batch” szavak után.
Már rendelkezik ezzel a termékkel?
Az Ön által nemrégiben megvásárolt termékekre vonatkozó dokumentumokat a Dokumentumtárban találja.
James G Jackson et al.
Cancer cell, 21(6), 793-806 (2012-06-16)
Studies on the role of TP53 mutation in breast cancer response to chemotherapy are conflicting. Here, we show that, contrary to dogma, MMTV-Wnt1 mammary tumors with mutant p53 exhibited a superior clinical response compared to tumors with wild-type p53. Doxorubicin-treated
Timothy C Hallstrom et al.
Proceedings of the National Academy of Sciences of the United States of America, 100(19), 10848-10853 (2003-09-05)
Previous work has demonstrated a role for the E2F1 gene product in signaling apoptosis, both as a result of the deregulation of the Rb/E2F pathway as well as in response to DNA damage. We now show that the ability of
Giovanna Ferrari-Amorotti et al.
Cancer research, 73(1), 235-245 (2012-10-12)
The process of epithelial-mesenchymal transition (EMT) which is required for cancer cell invasion is regulated by a family of E-box-binding transcription repressors, which include Snail (SNAIL1) and Slug (SNAI2). Snail appears to repress the expression of the EMT marker E-cadherin
Shou-Ching Tang et al.
Breast cancer research and treatment, 84(3), 203-213 (2004-03-18)
BAG-1, a recently identified anti-apoptotic protein, is overexpressed in the majority of invasive breast carcinomas. Overexpression of BAG-1 is important for both multi-step oncogenesis and resistance of cancer cells to apoptosis induced by DNA-damaging alkylating agents. BAG-1 protein species are
Timothy Budden et al.
Oncotarget, 7(38), 60940-60953 (2016-08-04)
UVB exposure leads to DNA damage, which when unrepaired induces C>T transitions. These mutations are found throughout the melanoma genome, particularly in non-transcribed regions. The global genome repair (GGR) branch of nucleotide excision repair (NER) is responsible for repairing UV-induced
Tudóscsoportunk valamennyi kutatási területen rendelkezik tapasztalattal, beleértve az élettudományt, az anyagtudományt, a kémiai szintézist, a kromatográfiát, az analitikát és még sok más területet.
Lépjen kapcsolatba a szaktanácsadással